Original fundamental research starts and ENDS here.
Sectors Tags Blog
MRK
30 filings
Timeline Columns Start Research 8-K Categories
2025
Q4 2 filings
Nov
Q3 2025 Results
Unable to extract specific revenue and EPS figures from provided XBRL metadata
10-Q
Oct
Q3 Earnings
Third quarter 2025 earnings report
8-K
Q3 3 filings
Sep
Debt Offering
$6B notes offering with rates from floating to 5.7%
8-K
Aug
Q2 2025 Results
Unable to extract specific revenue and EPS figures from provided XBRL metadata
10-Q
Jul
Q2 Earnings + $3B Restructuring Program
$3B restructuring costs, $1.7B annual savings by 2027
8-K
Q2 4 filings
May
Annual Shareholder Meeting
13 directors elected, executive comp approved, 4 shareholder proposals rejected
8-K
May
Q1 2025 Results
Financial data not available in provided content
10-Q
Apr
Q1 2025 Earnings
First quarter 2025 earnings results
8-K
Apr
2025 Proxy Statement
13 director nominees, Annual meeting May 27, 2025
DEF 14A
Q1 2 filings
Feb
FY24 2024 Results
Data insufficient - no clear revenue or EPS figures available in provided content
📌 Data insufficient - filing content appears to be primarily XBRL taxonomy references without substantive financial data or business highlights
10-K
Feb
Q4 2024 Earnings
Fourth quarter and year end 2024 results reported
8-K
2024
Q4 3 filings
Nov
New Director Elected, Bylaws Amended
Lal Karsanbhai elected to Board effective Jan 1, 2025; indemnification provisions updated
8-K
Nov
Q3 2024 Results
Unable to extract specific revenue and EPS figures from provided XBRL metadata
10-Q
Oct
Q3 Earnings
Q3 2024 earnings reported
8-K
Q3 2 filings
Aug
Q2 2024 Results
Financial data not available in provided content
10-Q
Jul
Q2 2024 Earnings
Second quarter 2024 earnings results
8-K
Q2 4 filings
May
€3.4B Debt Offering & Annual Meeting
€3.4B notes issued (3.25%-3.75% rates, 2032-2054 maturities); all directors re-elected
8-K
May
Q1 2024 Results
Unable to extract specific revenue or EPS figures from provided XBRL data
10-Q
Apr
Q1 2024 Earnings
Q1 2024 financial results reported
8-K
Apr
2024 Proxy Statement
CEO comp: Not specified, Say-on-pay: TBD
DEF 14A
Q1 3 filings
Feb
FY 2023 Results
Unable to extract specific revenue and EPS figures from provided XBRL metadata
📌 Multiple strategic partnerships and acquisitions including Daiichi Sankyo antibody-drug conjugate collaboration (October 2023), Prometheus Biosciences acquisition (June 2023), and planned Harpoon Therapeutics acquisition (forecast completion by June 2024)
10-K
Feb
Director Retirement
Peter C. Wendell retiring from Board at 2024 Annual Meeting (May 28, 2024)
8-K
Feb
Q4 Earnings + $4B Restructuring Program
$4B restructuring costs through 2031, 60% non-cash
8-K
2023
Q4 3 filings
Nov
Global Controller Change
Rita Karachun resigned, Dalton Smart III appointed effective Dec 4, 2023
8-K
Nov
Q3 2023 Results
Unable to extract specific revenue and EPS figures from provided XBRL metadata
10-Q
Oct
Q3 2023 Earnings
Third quarter 2023 earnings results reported
8-K
Q3 2 filings
Aug
Q2 2023 Results
Unable to extract specific revenue and EPS figures from provided XBRL metadata
10-Q
Aug
Q2 2023 Earnings
Second quarter 2023 earnings reported
8-K
Q2 2 filings
May
Annual Shareholder Meeting
13 directors elected, executive compensation approved 91.30%
8-K
May
Debt Offering
$5B multi-tranche notes offering, rates 4.05%-5.15%
8-K
SECENDS is not affiliated with the SEC. Data from public EDGAR filings. Not financial advice.